Form 4: S. Louise Phanstiel Reports Acquisition of Myriad Genetics Stock

Director S. Louise Phanstiel reports the acquisition of Myriad Genetics (MYGN) stock and restricted stock units.

Summary

• S. Louise Phanstiel, a director of Myriad Genetics Inc. (MYGN), filed a Form 4 with the SEC on June 7, 2024.
• The report details changes in beneficial ownership of Myriad Genetics securities.
• On June 6, 2024, Phanstiel acquired 15,695 shares of common stock and was granted restricted stock units.
• Following the transaction, Phanstiel directly owns 127,648 shares of common stock.
• Phanstiel also indirectly owns 33,119 shares through The Phanstiel Trust.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock transactions by a company director. The acquisition of shares could be seen as slightly positive.

Positives

• A director's acquisition of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The restricted stock units vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates